- Home
- ATHA vs CNFR Comparison
ATHA vs CNFR Comparison
Compare ATHA & CNFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- CNFR
- Stock Information
- Founded
- ATHA 2011
- CNFR 2009
- Country
- ATHA United States
- CNFR United States
- Employees
- ATHA N/A
- CNFR N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- CNFR Property-Casualty Insurers
- Sector
- ATHA Health Care
- CNFR Finance
- Exchange
- ATHA Nasdaq
- CNFR Nasdaq
- Market Cap
- ATHA 10.6M
- CNFR 9.5M
- IPO Year
- ATHA 2020
- CNFR 2015
- Fundamental
- Price
- ATHA $0.31
- CNFR $0.74
- Analyst Decision
- ATHA Buy
- CNFR
- Analyst Count
- ATHA 4
- CNFR 0
- Target Price
- ATHA $11.25
- CNFR N/A
- AVG Volume (30 Days)
- ATHA 1.3M
- CNFR 5.2K
- Earning Date
- ATHA 07-31-2025
- CNFR 08-12-2025
- Dividend Yield
- ATHA N/A
- CNFR N/A
- EPS Growth
- ATHA N/A
- CNFR N/A
- EPS
- ATHA N/A
- CNFR 1.96
- Revenue
- ATHA N/A
- CNFR $64,021,000.00
- Revenue This Year
- ATHA N/A
- CNFR $25.91
- Revenue Next Year
- ATHA N/A
- CNFR N/A
- P/E Ratio
- ATHA N/A
- CNFR $0.38
- Revenue Growth
- ATHA N/A
- CNFR N/A
- 52 Week Low
- ATHA $0.22
- CNFR $0.42
- 52 Week High
- ATHA $3.67
- CNFR $1.91
- Technical
- Relative Strength Index (RSI)
- ATHA 49.52
- CNFR 42.17
- Support Level
- ATHA $0.29
- CNFR $0.76
- Resistance Level
- ATHA $0.35
- CNFR $0.81
- Average True Range (ATR)
- ATHA 0.03
- CNFR 0.02
- MACD
- ATHA -0.00
- CNFR -0.01
- Stochastic Oscillator
- ATHA 14.10
- CNFR 1.14
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.